S. Vermeire

Publications670
h-index95
Citations36,678
Highly Influential Citations1,318
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • W. Sandborn
  • 1,901 Publications, 94,323 Citations
  • G. Van Assche
  • 345 Publications, 33,235 Citations
  • B. Feagan
  • 817 Publications, 46,011 Citations
  • P. Rutgeerts
  • 889 Publications, 29,314 Citations
  • Publications
  • Influence
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease
Crohn’s disease and ulcerative colitis, the two common forms of inflammatory bowel disease (IBD), affect over 2.5 million people of European ancestry, with rising prevalence in other populations.… Expand
  • 3,294
  • 170
  • PDF
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
BACKGROUND Treatment with infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, can result in the formation of antibodies against infliximab. We evaluated the clinical… Expand
  • 1,847
  • 71
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47
Genome-wide association studies and candidate gene studies in ulcerative colitis have identified 18 susceptibility loci. We conducted a meta-analysis of six ulcerative colitis genome-wide association… Expand
  • 1,204
  • 39
  • PDF
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis.
### 1.1 Introduction Ulcerative colitis is a lifelong disease arising from an interaction between genetic and environmental factors, observed predominantly in the developed countries of the world.… Expand
  • 663
  • 35
Laboratory markers in IBD: useful, magic, or unnecessary toys?
Laboratory markers have been investigated in inflammatory bowel disease (IBD) for diagnostic and differential diagnostic purposes, for assessment of disease activity and risk of complications, for… Expand
  • 735
  • 31
  • PDF
Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives
Background and aims A general dysbiosis of the intestinal microbiota has been established in patients with Crohn's disease (CD), but a systematic characterisation of this dysbiosis is lacking.… Expand
  • 645
  • 27
  • PDF
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
BACKGROUND Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely… Expand
  • 420
  • 27
  • PDF
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
OBJECTIVES:Infliximab (IFX) is successfully used in the treatment of inflammatory bowel diseases but some patients generate antibodies to IFX (ATI) jeopardizing the pharmacokinetics of the drug.… Expand
  • 290
  • 27
A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis
Objective Bacteria play an important role in the onset and perpetuation of intestinal inflammation in inflammatory bowel disease (IBD). Unlike in Crohn's disease (CD), in which dysbiosis has been… Expand
  • 728
  • 25
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease
Background: Episodic infliximab (IFX) treatment is associated with the formation of antibodies to IFX (ATIs) in the majority of patients, which can lead to infusion reactions and a shorter duration… Expand
  • 531
  • 21